Respiratory investigation最新文献

{"title":"Viscoelastic characteristics of spontaneous sputum obtained from patients with chronic productive cough in comparison to bronchial asthma","authors":"Haruhiko Ogawa ,&nbsp;Yuka Uchida ,&nbsp;Jeremy Patarin ,&nbsp;Lydia Esteban Enjuto ,&nbsp;Kazuhiro Ito","doi":"10.1016/j.resinv.2025.03.012","DOIUrl":"10.1016/j.resinv.2025.03.012","url":null,"abstract":"<div><h3>Background</h3><div>Chronic respiratory diseases are known to be associated with alterations in mucus rheology, but limited information is available regarding chronic cough. The aim of this study was to determine the sputum rheology in chronic productive cough (CPC) in comparison to bronchial asthma (BA).</div></div><div><h3>Methods</h3><div>The viscoelasticity profiles of spontaneous sputum obtained from 26 patients with CPC (10 sinobronchial syndrome [SBS], 16 non-SBS) and 25 patients with BA (12 mild-persistent, 7 moderate, and 6 severe) were analyzed by rheometry in a single center. The non-SBS group included fungus-associated chronic cough, post-COVID-19 cough, bronchorrhea, and unexplained chronic cough.</div></div><div><h3>Results</h3><div>Viscoelastic modulus (<em>G^∗</em>) and viscous modulus (<em>G″</em>) of the SBS group were similar to those of the total BA group. Although critical strain (<em>γ</em>_C) and critical stress (<em>σ</em>_C) tended to be larger in the BA group, and the former was comparable between the non-SBS group and the moderate or severe BA group. In the non-SBS group, <em>G″</em> was closely correlated with FeNO, and <em>γ</em>_C was inversely correlated with respiratory function, as in the BA group, but no such correlations were observed in the SBS group.</div></div><div><h3>Conclusions</h3><div>Quantitative rheological analysis revealed unique viscoelastic characteristics of spontaneous sputum and altered association with clinical biomarkers in the non-SBS group, in which the profile was more similar to BA than SBS in CPC. This new rheometer can identify features of sputum in patients with CPC that cannot be detected by conventional methods. Further investigations of sputum rheology in CPC are warranted to understand its pathogenesis.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 459-466"},"PeriodicalIF":2.4,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting sleep disordered breathing in middle-aged Japanese office workers: A simple and effective screening tool","authors":"Wakako Yamasawa ,&nbsp;Akiko Tanabe ,&nbsp;Koichiro Asano ,&nbsp;Yasunori Sato ,&nbsp;Hiromichi Matsushita ,&nbsp;Koichi Fukunaga","doi":"10.1016/j.resinv.2025.03.014","DOIUrl":"10.1016/j.resinv.2025.03.014","url":null,"abstract":"<div><h3>Background</h3><div>Sleep Disordered Breathing (SDB) is a common yet underdiagnosed condition, as many afflicted individuals are unaware of the condition. It is a major contributor to metabolic syndrome, sudden death, and deteriorating overall health, making early detection crucial, especially in populations such as Japanese office workers in whom symptoms may not be evident. This study aimed to fill the critical gap in SDB detection by investigating its prevalence among Japanese office workers unaware of any SDB symptoms and by and developing a straightforward, effective screening tool that can be integrated into routine health examinations.</div></div><div><h3>Methods</h3><div>A total of 518 male office workers underwent a sleep monitoring test along with a comprehensive questionnaire assessing lifestyle, comorbidities, and sleep quality. Participants were divided into derivation and validation cohorts to develop and test, respectively, an SDB prediction score.</div></div><div><h3>Results</h3><div>In this study, 149 (28.7 %) patients had a respiratory disturbance index ≥15 and moderate or severe SDB. The developed prediction model demonstrated a high sensitivity of 91.5 % and a specificity of 49.4 %, making it a powerful tool for early detection of SDB requiring treatment.</div></div><div><h3>Conclusions</h3><div>This study presents a convenient screening tool that could revolutionize SDB detection among Japanese office workers, leading to earlier interventions and potentially reducing the burden of related health complications. This tool holds significant promise for incorporation into standard health examinations, offering a proactive approach to managing SDB.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 453-458"},"PeriodicalIF":2.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term, real-world effectiveness of biologics for severe uncontrolled asthma: The PROSPECT study","authors":"Kazuhisa Asai ,&nbsp;Takashi Iwanaga ,&nbsp;Mai Takahashi ,&nbsp;Masahiro Eda ,&nbsp;Takehiro Hirai ,&nbsp;Tadataka Yabuta ,&nbsp;Naoyuki Makita ,&nbsp;Yuji Tohda","doi":"10.1016/j.resinv.2025.03.007","DOIUrl":"10.1016/j.resinv.2025.03.007","url":null,"abstract":"<div><h3>Background</h3><div>Several biologics (BIOs) are available to treat severe uncontrolled asthma. However, there are limited data regarding their long-term effectiveness in real-world clinical practice. We investigated the long-term, over 24 months, effectiveness of initiating a BIO in patients with severe uncontrolled asthma deemed candidates for BIO therapy.</div></div><div><h3>Methods</h3><div>PROSPECT was a multicenter observational cohort study that enrolled patients with severe uncontrolled asthma in Japan. We divided the patients into two groups according to whether they did (BIO group) or did not (non-BIO group) initiate a BIO within 12 weeks of enrollment. The BIO (omalizumab, mepolizumab, benralizumab, and dupilumab) was chosen at the physician's discretion considering the patient's asthma phenotype.</div></div><div><h3>Results</h3><div>Of 306 patients enrolled, 285 were included in the full analysis set (BIO group: <em>n</em> = 125; non-BIO group: <em>n</em> = 160). The adjusted least-squares mean change in post-bronchodilator forced expiratory volume in 1 s at 24 months was 0.17 L (95% confidence interval [CI]: 0.11 to 0.23) and 0.04 L (95% CI: −0.02 to 0.10) in the BIO and non-BIO groups, respectively (adjusted difference: 0.13 L; 95% CI: 0.04 to 0.21, <em>P</em> = 0.004). The changes from baseline to 6, 12, and 18 months were significantly greater in the BIO group. Reduction in asthma exacerbations, improvement in 5-item Asthma Control Questionnaire scores, decreased daily oral corticosteroid doses, and higher oral corticosteroid withdrawal rate were observed in the BIO group.</div></div><div><h3>Conclusions</h3><div>Initiation of a BIO was associated with significant improvements in long-term lung function and asthma control among patients with severe uncontrolled asthma in real-world clinical practice.</div></div><div><h3>Trial registration</h3><div>University Hospital Medical Information Network clinical trials registry (Japan), UMIN000038006. First registered: September 13, 2019.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 444-452"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of high fraction of inspired oxygen and high flow on exercise tolerance in patients with COPD and IPF: A randomized crossover trial","authors":"Yuichi Chihara,&nbsp;Tomomasa Tsuboi,&nbsp;Kensuke Sumi,&nbsp;Hiromasa Tachibana,&nbsp;Atsuo Sato","doi":"10.1016/j.resinv.2025.03.016","DOIUrl":"10.1016/j.resinv.2025.03.016","url":null,"abstract":"<div><h3>Background</h3><div>The effect of combining high fraction of inspired oxygen (F_IO₂) and high flow through a high-flow nasal cannula (HFNC) on exercise tolerance in chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) remains unclear.</div></div><div><h3>Methods</h3><div>This prospective, single-blind, randomized, crossover study included patients with COPD (n = 25) and IPF (n = 25). The patients performed a 6-min walking test (6 MWT) while attached to a battery-supplied portable HFNC device under the following four conditions: F_IO₂ set to a minimum percutaneous oxygen saturation (SpO₂) of 86–88 % during 6 MWT with a flow rate of 10 L/min (LOLF) or 50 L/min (LOHF); and F_IO₂ set to a minimum SpO₂ of 92–94 % with a flow rate of 10 L/min (HOLF) or 50 L/min (HOHF).</div></div><div><h3>Results</h3><div>In both groups, the 6-min walking distance (6 MWD) was significantly greater for HOHF than for LOLF (COPD: 323.2 ± 77.6 m vs. 268.6 ± 87.3 m, respectively, p &lt; 0.0001 and IPF: 406 ± 50.7 m vs. 372.3 ± 50.9 m, respectively, p &lt; 0.0001).</div><div>In the analysis of the interaction effects for the 6 MWD, the combination of high F_IO₂ and high flow resulted in an additional 15.9-m extension of the 6 MWD (95 % confidence interval: 0.34–31.5; p = 0.050). The interaction between IPF and high-flow was −14.0 m, suggesting a less pronounced extension effect compared with COPD (95 % confidence interval: −29.5–1.6; p = 0.085).</div></div><div><h3>Conclusion</h3><div>The combination of high F_IO₂ and high flow through an HFNC may improve exercise tolerance in patients with COPD and IPF.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 431-437"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal dysfunction during osimertinib treatment in patients with non–small cell lung cancer positive for EGFR mutations","authors":"Yui Miyazaki ,&nbsp;Eiji Iwama ,&nbsp;Hiroaki Ogata ,&nbsp;Ritsu Ibusuki ,&nbsp;Daisuke Shibahara ,&nbsp;Kohei Otsubo ,&nbsp;Yoshimasa Shiaraishi ,&nbsp;Yasuto Yoneshima ,&nbsp;Kumiko Torisu ,&nbsp;Isamu Okamoto","doi":"10.1016/j.resinv.2025.03.015","DOIUrl":"10.1016/j.resinv.2025.03.015","url":null,"abstract":"<div><h3>Background</h3><div>Osimertinib is a standard treatment for non–small cell lung cancer (NSCLC) positive for <em>EGFR</em> activating mutations. Although renal dysfunction associated with osimertinib treatment is reported to be rare, detailed information on this adverse effect is needed because cytotoxic drugs such as pemetrexed are also widely administered for NSCLC but cannot be used in individuals with renal dysfunction.</div></div><div><h3>Methods</h3><div>We retrospectively collected clinical data including the serum creatinine concentration and estimated glomerular filtration rate (eGFR) during osimertinib treatment for 130 NSCLC patients.</div></div><div><h3>Results</h3><div>Serum creatinine and eGFR worsened gradually during osimertinib treatment, with the median value of creatinine at the point of greatest deterioration differing significantly from that at baseline (0.93 versus 0.72 mg/dL, <em>P</em> &lt; 0.01). Seventy patients (54 %) experienced worsening of the CTCAE grade for creatinine increased, with the frequency of patients with grade 1 or 2 being increased significantly (<em>P</em> &lt; 0.01) at the point of greatest deterioration relative to baseline (grade 1, 46.9 % versus 14.6 %; grade 2, 14.6 % versus 0.8 %, respectively). A higher serum creatinine level at baseline was a significant risk factor for worsening of the CTCAE grade (odds ratio of 1.66, <em>P</em> &lt; 0.001). The median serum creatinine and eGFR at 4 weeks after osimertinib discontinuation had improved to levels similar to those for baseline.</div></div><div><h3>Conclusions</h3><div>Renal dysfunction occurred frequently during osimertinib treatment but was ameliorated after drug discontinuation, suggesting that, although renal function should be carefully monitored, its impairment is not likely to affect subsequent chemotherapy in most patients.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 438-443"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of second line and subsequent treatments of small cell lung cancer with and without immune checkpoint inhibitor combination therapy","authors":"Daisuke Morinaga ,&nbsp;Jun Sakakibara-Konishi ,&nbsp;Yasutaka Kawai ,&nbsp;Yumi Morinaga ,&nbsp;Shohei Mizobuchi ,&nbsp;Yoshihiro Okamoto ,&nbsp;Yasunari Yamanaka ,&nbsp;Kei Takahashi ,&nbsp;Hajime Kikuchi ,&nbsp;Noriaki Sukoh ,&nbsp;Taichi Takashina ,&nbsp;Hidenori Kitai ,&nbsp;Satoshi Konno","doi":"10.1016/j.resinv.2025.03.013","DOIUrl":"10.1016/j.resinv.2025.03.013","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy (ICI-chemo) have become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, the effect of ICI-chemo on the efficacy of subsequent chemotherapy remains unknown. This study aimed to investigate the efficacy of second and subsequent treatments of SCLC with and without ICI combination therapy.</div></div><div><h3>Methods</h3><div>We performed an analysis of patients with ES-SCLC between January 2015 and June 2023. The ICI-chemo groups were defined as patients who received ICI-chemo as first-line therapy between September 2019 and June 2023, after ICI-chemo was reimbursed in Japan. The non–ICI–chemo groups were defined as patients who received platinum-doublet therapy between January 2015 and August 2019 and were considered eligible for ICI-chemo.</div></div><div><h3>Results</h3><div>In total, 224 patients were included (91 and 133 patients who received ICI-chemo and non–ICI–chemo, respectively). There were no significant differences in patient characteristics between the groups. There was no significant difference in progression-free survival (PFS) and overall survival (OS) for first-line treatment between the two groups. The median PFS and OS periods for second-line treatment were 3.9 and 3.9 months and 10.3 and 10.7 months in the ICI-chemo and non–ICI–chemo groups, respectively, without significant difference. Most patients in both groups received amrubicin as the second-line treatment. Moreover, the PFS and OS periods for third-line treatment were not significantly different between the ICI-chemo and non–ICI–chemo groups.</div></div><div><h3>Conclusions</h3><div>In ES-SCLC, there is no significant additive effect on PFS and OS of second- and subsequent line treatments following ICI-chemo at first-line treatment.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 423-430"},"PeriodicalIF":2.4,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143684755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of the 11th wave by SARS-CoV-2 KP.3 subvariant: Re-increase in pneumonia severity","authors":"Naoyuki Miyashita ,&nbsp;Yasushi Nakamori ,&nbsp;Makoto Ogata ,&nbsp;Naoki Fukuda ,&nbsp;Akihisa Yamura ,&nbsp;Tomoki Ito","doi":"10.1016/j.resinv.2025.03.001","DOIUrl":"10.1016/j.resinv.2025.03.001","url":null,"abstract":"<div><h3>Objectives</h3><div>We investigated the incidence and risk factors for requiring intensive care unit (ICU) admission or invasive mechanical ventilation (IMV) in pneumonia patients with Omicron subvariants between the 9th and 11th waves.</div></div><div><h3>Methods</h3><div>We analyzed 536 patients with pneumonia caused by SARS-CoV-2 Omicron subvariants (175 cases were XBB lineage, 169 cases were JN.1, and 192 cases were KP.3 subvariants).</div></div><div><h3>Results</h3><div>Rates of ICU admission or requirement for IMV were significantly higher in patients with the KP.3 subvariant group than those with the XBB lineage and JN.1 subvariant groups. Patient age (odds ratio [OR]: 1.09, <em>P</em> &lt; 0.001), immunodeficiency (OR: 2.82), 2 or more co-morbid illnesses (OR: 2.54), and more than 2 years since last vaccination (OR: 1.29) were significantly associated with increased severity.</div></div><div><h3>Conclusions</h3><div>Physicians should recommend SARS-CoV-2 vaccination and positive use anti-SARS-CoV-2 drugs when COVID-19 is found in patients who are ≥65 years old or who have multiple comorbidities.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 401-404"},"PeriodicalIF":2.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: “Factors associated with readmission for community-onset pneumonia among older people: A retrospective study”","authors":"Fnu Mubashirah","doi":"10.1016/j.resinv.2025.03.011","DOIUrl":"10.1016/j.resinv.2025.03.011","url":null,"abstract":"","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Page 422"},"PeriodicalIF":2.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Guidelines for Asthma Management (PGAM): Digest edition","authors":"Jun Tamaoki ,&nbsp;Hiroyuki Nagase ,&nbsp;Hiroyuki Sano ,&nbsp;Takeshi Kaneko ,&nbsp;Yasuhiro Gon ,&nbsp;Nobuaki Miyahara ,&nbsp;Hironori Sagara ,&nbsp;Akihiko Tanaka ,&nbsp;Takahiko Horiguchi ,&nbsp;Etsuko Tagaya ,&nbsp;Tomohiro Akaba ,&nbsp;Yuji Tohda ,&nbsp;the PGAM committee in the Japan Asthma Society","doi":"10.1016/j.resinv.2025.03.009","DOIUrl":"10.1016/j.resinv.2025.03.009","url":null,"abstract":"<div><div>The international and national guidelines for asthma management are typically comprehensive and designed for respiratory specialists, making them less practical for primary care physicians who handle most asthma cases. Recognizing the need for more accessible guidelines, the Japan Asthma Society developed the Practical Guidelines for Asthma Management (PGAM). PGAM aims to provide a concise summary of key asthma management principles, increasing awareness, education, and support among nonspecialists and patients alike. It includes user-friendly tables and lists outlining common symptoms, triggers, diagnostic criteria, and basic management strategies, along with frequently encountered treatable traits and comorbidities. These elements are presented through simple, clinically relevant algorithms. A notable feature of PGAM is the “Basic Roadmap for Asthma Management,” which outlines a clear sequence for patient assessment, diagnosis, and treatment from initial consultation onward, offering an easy-to-follow visual guide. Additionally, the guidelines include methods for assessing airway inflammation, enabling patient phenotyping and endotyping. This supports a personalized treatment approach, particularly with biologics, aimed at achieving clinical remission.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 405-421"},"PeriodicalIF":2.4,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143654466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of oligometastasis in older patients with extensive-stage small cell lung cancer","authors":"Daisuke Morinaga ,&nbsp;Kana Hashimoto ,&nbsp;Hajime Asahina ,&nbsp;Hisashi Tanaka ,&nbsp;Osamu Honjo ,&nbsp;Toshiyuki Harada ,&nbsp;Hiroshi Yokouchi ,&nbsp;Hajime Kikuchi ,&nbsp;Ryota Shigaki ,&nbsp;Taichi Takashina ,&nbsp;Keiichi Nakamura ,&nbsp;Yasutaka Kawai ,&nbsp;Mamoru Takahashi ,&nbsp;Ryotaro Kida ,&nbsp;Noriaki Sukoh ,&nbsp;Kenichiro Ito ,&nbsp;Ayumu Takahashi ,&nbsp;Hirofumi Hommura ,&nbsp;Yoshihito Ohhara ,&nbsp;Megumi Furuta ,&nbsp;Satoshi Oizumi","doi":"10.1016/j.resinv.2025.03.008","DOIUrl":"10.1016/j.resinv.2025.03.008","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitor plus chemotherapy (ICT) is the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). We previously reported that oligometastasis (OM) is a predictor of ICT efficacy, however, the relationship between ICT efficacy and OM in older patients remains unknown. Therefore, this study examined the efficacy of ICT in the older patients including the influence of OM.</div></div><div><h3>Methods</h3><div>We enrolled patients with ES-SCLC who received ICT as first-line treatment between September 2019 and June 2022. Patient characteristics and treatment efficacy were compared between older (≥75 years) and non-older (&lt;75 years) patients.</div></div><div><h3>Results</h3><div>We enrolled 228 patients, including 42 older patients. The prevalence of synchronous oligometastasis (SOM) at the start of first-line treatment was 21.0 % and 21.4 % (p = 1.0) in the older and non-older groups, respectively. The progression-free survival (PFS) with first-line therapy was 5.4 and 4.5 months (p = 0.55) and overall survival (OS) was 11.5 and 12.6 months (p = 0.74) for the SOM and non-SOM subgroups in the older group, respectively. For second-line treatment, PFS was 4.5 and 6.3 months (p = 0.79), and OS after second-line initiation was 16.0 and 13.2 months (p = 0.55) in oligoprogression (OP) and non-OP patients in the older group, respectively.</div></div><div><h3>Conclusions</h3><div>The frequencies of SOM and OP were not significantly different between older and non-older patients. Although the small number of older patients in this study makes it impossible to conclude definitively, we did not observe a significant prognostic prolongation in older patients with OM as in non-older patients.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 3","pages":"Pages 373-382"},"PeriodicalIF":2.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}